Zobrazeno 1 - 10
of 1 069
pro vyhledávání: ''
Autor:
Ferdinando Riccardi, Bruno Chiurazzi, Raffaella Ruocco, Francesca Ambrosio, Maria Fiorella Brangi, Carmela Barbato, Vincenzo Di Lauro, Dario Arundine, M. Biglietto, Roberto Fiorentino, Francesco Jacopo Romano, Maresa Cammarota, Sarah Scagliarini, Livio Puglia, Ivana Cerillo, Carmen Mocerino
Publikováno v:
Oncotarget
The stock of therapeutic weapons available in metastatic colorectal cancer (mCRC) has been progressively grown over the years, with improving both survival and patients' clinical outcome: notwithstanding advances in the knowledge of mCRC biology, as
Publikováno v:
Oncotarget
Immunotherapy has been established as a standard of care for patients with malignant melanoma, however, the long-term side-effects of immunotherapy are still emerging. Studies over the last decade have documented increasing reports of endocrine dysfu
Autor:
Barry C. Johnson, Esther Mena, Nancy Moore, Cecilia Monge Bonilla, Frank I. Lin, Lamin Juwara, James H. Doroshow, Geraldine O'Sullivan Coyne, Matthew M. Ames, Matthew P. Goetz, Alice P. Chen, M. Liza Lindenberg, Larry Rubinstein, S. Kummar, Howard Streicher, Renee M. McGovern, Joseph M. Covey, Peter L. Choyke, Joel M. Reid, Richard Piekarz, Rachel Bishop, Naoko Takebe, Jerry M. Collins
Publikováno v:
Oncotarget
Background: Differential responses to tamoxifen may be due to inter-patient variability in tamoxifen metabolism into pharmacologically active Z-endoxifen. Z-endoxifen administration was anticipated to bypass these variations, increasing active drug l
Autor:
Karam Khaddour, Joshua Dowling, Jiayi Huang, Martha Council, David Chen, Lynn Cornelius, Tanner Johanns, Sonika Dahiya, George Ansstas
Publikováno v:
Oncotarget
Despite the substantial advances in the management of metastatic melanoma with the introduction of immune checkpoint inhibitors (ICI), many patients develop disease progression during treatment with immunotherapy. This has been suggested to be mediat
Publikováno v:
Oncotarget
Overexpression of the HER2 receptor occurs in approximately 20% of breast cancer patients. HER2 positivity is associated with poor prognosis and aggressive tumour phenotypes, which led to rapid progress in HER2 targeted therapeutics and diagnostic te
Autor:
Navin Srivastava, Jinumary John, Sanket Patil, Ajay Srinivasan, Sachin Apurwa, Pradip Devhare, Prashant Kumar, Rajnish Nagarkar, Aditya Shreenivas, Zarrine Raazi, Janani Sambath, Sewanti Limaye, Darshana Patil, Rajan Datar, Ashwini Ghaisas, Dadasaheb Akolkar
Publikováno v:
Oncotarget
Periampullary adenocarcinomas are rare neoplasm that originates from the pancreatic head, the ampulla of vater, the distal bile duct or the duodenum. Surgical resection followed by adjuvant therapy is considered as the standard of care treatment for
Publikováno v:
Oncotarget
Ovarian aging is associated with significant changes in the structural organization of collagen, resulting in ovarian fibrosis. In many other tissues, fibrosis increases risks associated with tumorigenesis and metastasis. Thus, it is possible that ov
Autor:
O A Bogomolov, Irina V. Chepurnaya, Natalia Yu Neklasova, G. M. Zharinov, Vladimir N. Anisimov
Publikováno v:
Oncotarget
Background: The antitumor and immunomodulating activities of melatonin are widely known. These activities are based upon the multifactorial mechanism of action on various links of carcinogenesis. In the present paper, the long-term results of the cli
Autor:
Jordan K Yoeli, Yamileth Hernandez, Bobby Guillory, Pu Zang, Haiming Liu, Jiaohua Luo, Alison Tewnion, Mackenzie Storie, Barbara G. Anderson, Jose M. Garcia, Ji-an Chen, Ian In-Gi Lee
Publikováno v:
Oncotarget. 11:3286-3302
Adipose tissue (AT) atrophy is a hallmark of cancer cachexia contributing to increased morbidity/mortality. Ghrelin has been proposed as a treatment for cancer cachexia partly by preventing AT atrophy. However, the mechanisms mediating ghrelin's effe
Autor:
Stefano Stabile, Constantin Volovat, Piotr Koralewski, Krassimir Koynov, Iulian Bobe, Adina Croitoru, Juneko E. Grilley Olson, Tudor-Eliade Ciuleanu, Giulio Cerea, Atsushi Osada, Simona Ruxandra Volovat
Publikováno v:
Oncotarget
NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity,